Open access
Aug 2026
A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/NgR/ROCK Signaling Pathway
To evaluate the therapeutic effects of NAP2, a novel NgR1 antagonist peptide, on Alzheimer's disease (AD) pathology and to determine whether inhibition of the Nogo‐A/NgR1/ROCK signaling axis can ameliorate neurodegenerative alterations in APP/PS1 mice.
Zheng Zhang, Hui-Min Tan, Fang Shi et al.
· CNS Neuroscience & Therapeut... · 0 citations